Celon launches an emulsion-based drug to treat Black Fungus

The drug is set to provide much needed respite to patients reeling under the severe impact of the second wave of C-19 and the resultant Black Fungus.

Medicine Injection
Picture: Pixabay

Hyderabad based specialty biopharmaceutical manufacturer, Celon Laboratories, announced the launch of an alternative drug – Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus.

The drug is set to provide much needed respite to patients reeling under the severe impact of the second wave of C-19 and the resultant Black Fungus.

Also read more articles on Black fungus, click here

Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among C-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids.

Also read another articles on  Amphotericin B, click here

Medicine Injection
Picture: Pixabay

To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation.

Developed by Celon’s in-house R&D team in a record three weeks, the emulsion-based formulation will provide leading hospitals and C-19 treatment centers with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.

Celon Labs’ Managing Director, Mr. M. Nagesh Kumar, spoke of Celon’s role during India’s second wave of C-19: “Celon Labs is deeply committed to supporting the ongoing efforts to combat the C-19 pandemic during this deadly second wave and to save as many lives as possible.

The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the domestic market soon.”

Additionally, the Chairman of Celon, Mr. Hocine Sidi-Said, expressed his gratitude to employees for achieving this important milestone: “I am delighted to see that Celon Labs has mobilized its talents and expertise to swiftly respond to this pressing medical need. I am grateful to the team at Celon Labs who have made the launch of Amphotericin B Emulsion possible.”

PLI Scheme: Approvals accorded for Promotion of APIs

Zydus Cadila plans to test its C-19 vaccine for 5-12 age…

Black fungus treatment: IIT is ready for tech transfer of oral…

Take care of your Air, Don’t share it

Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets

NITI Aayog + Piramal to invest Rs 100 crores towards C-19…

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner